Tags

Type your tag names separated by a space and hit enter

The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.
Pharmacoepidemiol Drug Saf. 2008 Aug; 17(8):782-6.PD

Authors+Show Affiliations

Duke Translational Medicine Institute, Durham, NC 27715, USA. robert.califf@duke.eduNo affiliation info available

Pub Type(s)

Journal Article
Comment

Language

eng

PubMed ID

18655016

Citation

Califf, Robert M., and Judith M. Kramer. "The Balance of Benefit and Safety of Rosiglitazone: Important Lessons for Our System of Drug Development and Postmarketing Assessment." Pharmacoepidemiology and Drug Safety, vol. 17, no. 8, 2008, pp. 782-6.
Califf RM, Kramer JM. The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment. Pharmacoepidemiol Drug Saf. 2008;17(8):782-6.
Califf, R. M., & Kramer, J. M. (2008). The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment. Pharmacoepidemiology and Drug Safety, 17(8), 782-6. https://doi.org/10.1002/pds.1617
Califf RM, Kramer JM. The Balance of Benefit and Safety of Rosiglitazone: Important Lessons for Our System of Drug Development and Postmarketing Assessment. Pharmacoepidemiol Drug Saf. 2008;17(8):782-6. PubMed PMID: 18655016.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment. AU - Califf,Robert M, AU - Kramer,Judith M, PY - 2008/7/26/pubmed PY - 2008/10/28/medline PY - 2008/7/26/entrez SP - 782 EP - 6 JF - Pharmacoepidemiology and drug safety JO - Pharmacoepidemiol Drug Saf VL - 17 IS - 8 SN - 1099-1557 UR - https://www.unboundmedicine.com/medline/citation/18655016/The_balance_of_benefit_and_safety_of_rosiglitazone:_important_lessons_for_our_system_of_drug_development_and_postmarketing_assessment_ L2 - https://doi.org/10.1002/pds.1617 DB - PRIME DP - Unbound Medicine ER -